INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AVITA Medical, Inc. - RCEL

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices by AVITA Medical, Inc. and its officers or directors, following significant financial issues reported by the company [1][3]. Financial Performance - On August 7, 2025, AVITA reported a six-month backlog in unpaid provider claims for Recell procedures, which negatively impacted first-half demand [3]. - The backlog was attributed to contractors from the Centers for Medicare & Medicaid Services failing to assign adequate pricing and timely adjudication of claims, leading to uncertainty among providers and reduced utilization of Recell procedures [3]. - Following the announcement, AVITA's stock price dropped by $1.13, or 21%, closing at $4.25 per share on August 8, 2025 [3].